Fisher & Paykel Healthcare's revenue for the
six
months ended in Mar. 2026 was A$1,007 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was A$1,988 Mil.
Fisher & Paykel Healthcare's Revenue per Share for the
six
months ended in Mar. 2026 was A$1.71.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$3.37.
During the past 12 months, the average Revenue per Share Growth Rate of Fisher & Paykel Healthcare was 80.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Fisher & Paykel Healthcare's highest 3-Year average Revenue per Share Growth Rate was 26.20% per year. The lowest was -8.50% per year. And the median was 10.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Fisher & Paykel Healthcare Revenue Related Terms
Fisher & Paykel Healthcare Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Revenue distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1,988 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a Revenue of A$1,988 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Fisher & Paykel Healthcare and its competitors.
Is Fisher & Paykel Healthcare's Revenue too high?
Fisher & Paykel Healthcare's current Revenue is A$1,988 Mil. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Revenue compare to ISRG and BDX?
Fisher & Paykel Healthcare's Revenue of A$1,988 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Fisher & Paykel Healthcare and its competitors. Fisher & Paykel Healthcare's current Revenue is A$1,988 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.30, compared to a current price of A$33.49 — trading 7.7% below its estimated fair value. The current Revenue is A$1,988 Mil. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Revenue is A$1,988 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$33.49 is trading 7.7% below its estimated GF Value™ of A$36.30.
GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.
Key valuation signals for ASX:FPH:
Revenue: A$1,988 Mil
GF Value™: A$36.30 vs. price of A$33.49 (7.7% below fair value)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score
Get the complete analysis for ASX:FPH
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
